Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | TYK2 | P29597 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 4/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14997511 | 0.95 | JAK2 (0.37) | JAK2JAK1TYK2JAK3FYN | |
| SCHEMBL8832451 | 0.92 | MCHR1 (0.42) | JAK2JAK1TYK2JAK3FYN | |
| SCHEMBL14997518 | 0.89 | CHEK1 (0.41) | JAK2JAK1TYK2JAK3FDPS | |
| SCHEMBL14997526 | 0.87 | JAK2 (0.43) | JAK2JAK1TYK2JAK3FDPS | |
| SCHEMBL8828298 | 0.87 | CHEK1 (0.42) | JAK2JAK1TYK2JAK3MCHR1 | |
| SCHEMBL14997525 | 0.85 | CHEK1 (0.36) | JAK2JAK1TYK2JAK3FYN | |
| SCHEMBL14997524 | 0.84 | CHEK1 (0.41) | JAK2JAK1TYK2JAK3CHEK1 | |
| SCHEMBL14997507 | 0.84 | CHEK1 (0.42) | JAK2JAK1TYK2JAK3FDPS | |
| SCHEMBL14997516 | 0.82 | JAK2 (0.41) | JAK2JAK1TYK2JAK3FDPS | |
| SCHEMBL12922036 | 0.80 | MAPT (0.38) | MCHR1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249154-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | WU ZHANGGUI (US) | 2016-02-02 | — | — | US | disclosed |
| US-20130143887-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2013-06-06 | — | — | US | disclosed |
| US-8318740-B2 | Compounds for protein kinase inhibition | WU ZHANGGUI (US) | 2012-11-27 | — | — | US | disclosed |
| US-20090275585-A1 | Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition | WU ZHANGGUI | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275585-A1 | Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition | CHEK2, CHEK1, PLK1 | JAK2 1239/4885JAK1 1565/4885TYK2 893/4885 |
| US-20130143887-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | CHEK2, CHEK1, PLK1 | JAK2 1239/4885JAK1 1565/4885TYK2 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.